FULC   $4.36  -2.68% Market Closed After Close 4.37 0.23%

Fulcrum Therapeutics Inc
Last Events:

2023-08-09 Signal in Stochastic changed from bullish to bullish recovery. The stochastic indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: main and signal line crossing.

2023-08-09 Trend Power changed from almost flat to slow.

2023-08-06 Signal in Stochastic changed from bearish to bullish. The stochastic indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: up-crossing the middle level.

2023-08-06 Signal in MACD changed from bullish weakening to bullish recovery. Oscillator MACD is in the positive territory it's lower than the signal line and grows. These factors mean that positive mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-08-05 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-04 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: main and signal line crossing.

2023-08-04 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-02 Trend pattern changed from расширяющийся канал to сужающийся канал.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 6
Target Price Mean 5.67
Mean unverified/preliminary 5.67 / 5.67
Target Price Low / High 2.00 / 14.00
Median / STD DEV 4.00 / 4.27
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd None None None
stoch ActivelyBuy None None
ma20 Sell Sell Sell
ma50 Sell None None
ma100 Sell Sell Sell
Candlestick PatternJan. 2, 2025 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US3596161097
ceo Mr. Alexander C. Sapir
Website https://www.fulcrumtx.com
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.